Role of Frailty in Bleeding Risk Prediction in Acute Coronary Syndrome

ConditionsFrailty Acute Coronary Syndrome Bleeding

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age65+

SponsorAssiut University

About this trial

Studying the incremental role of frailty in predicting in-hospital, short-term (30 days), and mid-term (6 months) bleeding in ACS patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

- Patients must be suffering from acute coronary syndrome ( STEMI - NSTEMI ) at the time of recruitment

- Patients must be older than 65 years

Disqualifiers

- Patients younger than 65 years

- Refusal of participation

- In - hospital death unrelated to bleeding

Trial population

Patients presenting with acute coronary syndrome ( STEMI and NSTEMI) and are older than 65 years

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Bleeding Academic Research Consortium ( BARC ) type 3 to 5

Type 3: Major bleeding (with subtypes) 3a: Overt bleeding plus hemoglobin drop of 3-5 g/dL, or Transfusion with ≤2 units of blood. 3b: Hemoglobin drop ≥5 g/dL, Cardiac tamponade, Bleeding requiring surgical intervention, or Bleeding requiring intravenous vasoactive agents. 3c: Intracranial hemorrhage (excluding microbleeds), Intraocular bleeding compromising vision. Type 4: CABG-related bleeding Perioperative bleeding within 48 hours of coronary artery bypass grafting (CABG) and Reoperation for bleeding, ≥5 units of blood transfused, Chest tube output ≥2 L in 24 hours, or Cardiac tamponade. Type 5: Fatal bleeding 5a: Probable fatal bleeding (no autopsy or imaging confirmation). 5b: Definite fatal bleeding (confirmed by autopsy or imaging)

Time frame

Baseline

Secondary outcomes

Bleeding Academic Research Consortium ( BARC ) type 0, 1 or 2

Type 0 : no bleeding Type 1: Bleeding that is not actionable and does not require medical attention Type 2 : Any bleeding that requires medical attention, hospitalization, or evaluation by a health care professional. but does not meet criteria for type 3, 4 or 5.

Time frame

Baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: